KIR polymorphisms modulate peptide-dependent binding to an MHC class I ligand with a Bw6 motif.

Abstract

Molecular interactions between killer immunoglobulin-like receptors (KIRs) and their MHC class I ligands play a central role in the regulation of natural killer (NK) cell responses to viral pathogens and tumors. Here we identify Mamu-A100201 (Mamu-A02), a common MHC class I molecule in the rhesus macaque with a canonical Bw6 motif, as a ligand for Mamu-KIR3DL05. Mamu-A100201 tetramers folded with certain SIV peptides, but not others, directly stained primary NK cells and Jurkat cells expressing multiple allotypes of Mamu-KIR3DL05. Differences in binding avidity were associated with polymorphisms in the D0 and D1 domains of Mamu-KIR3DL05, whereas differences in peptide-selectivity mapped to the D1 domain. The reciprocal exchange of the third predicted MHC class I-contact loop of the D1 domain switched the specificity of two Mamu-KIR3DL05 allotypes for different Mamu-A100201-peptide complexes. Consistent with the function of an inhibitory KIR, incubation of lymphocytes from Mamu-KIR3DL05(+) macaques with target cells expressing Mamu-A1*00201 suppressed the degranulation of tetramer-positive NK cells. These observations reveal a previously unappreciated role for D1 polymorphisms in determining the selectivity of KIRs for MHC class I-bound peptides, and identify the first functional KIR-MHC class I interaction in the rhesus macaque. The modulation of KIR-MHC class I interactions by viral peptides has important implications to pathogenesis, since it suggests that the immunodeficiency viruses, and potentially other types of viruses and tumors, may acquire changes in epitopes that increase the affinity of certain MHC class I ligands for inhibitory KIRs to prevent the activation of specific NK cell subsets.

Department

Description

Provenance

Subjects

T-Lymphocytes, Jurkat Cells, Animals, Macaca mulatta, Humans, Simian Acquired Immunodeficiency Syndrome, Peptides, Potassium Channels, Inwardly Rectifying, Histocompatibility Antigens Class I, HLA-B Antigens, Epitopes, T-Lymphocyte, Cloning, Molecular, Transfection, Protein Conformation, Protein Binding, Polymorphism, Single Nucleotide, Host-Pathogen Interactions

Citation

Published Version (Please cite this version)

10.1371/journal.ppat.1001316

Publication Info

Colantonio, Arnaud D, Benjamin N Bimber, William J Neidermyer, R Keith Reeves, Galit Alter, Marcus Altfeld, R Paul Johnson, Mary Carrington, et al. (2011). KIR polymorphisms modulate peptide-dependent binding to an MHC class I ligand with a Bw6 motif. PLoS pathogens, 7(3). p. e1001316. 10.1371/journal.ppat.1001316 Retrieved from https://hdl.handle.net/10161/28768.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Scholars@Duke

Reeves

Roger Keith Reeves

Professor in Surgery

Dr. Reeves obtained his Ph.D. at the University of Alabama-Birmingham studying dendritic cell biology in lentivirus infections, then completed his postdoctoral training in lentivirus vaccinology, natural killer cells, and innate immunity at the New England Primate Research Center, Massachusetts General Hospital, and Harvard Medical School (HMS). He later became faculty at HMS and Beth Israel Deaconess Medical Center through the rank of Associate Professor. Upon being recruited to Duke University in 2021, Dr. Reeves became a tenured Professor in the Department of Surgery and the Department of Pathology and Director in the Duke Center for Human Systems Immunology. He currently serves as Editor-in-Chief of the journal AIDS Research and Human Retroviruses and is the immediate past chair of the NIH HIV Immunopathogenesis and Vaccine Development study section.  Dr. Reeves also previously sat on NIH F13 fellowship study sections, has served on the HVTN ESI Advisory board for over a decade, and currently is Director of the Duke Center for AIDS Research Developmental Core, collectively mentoring dozens of trainees at all levels. Dr. Reeves’ research has been continuously supported by NIH for well over 15 years, having served as PI on multiple R and P grants  in addition to participating in consortia grants such as the HIV Vaccine Trials Network and BEAT-HIV Delaney Cure Collaboratory. Considered a global expert in natural killer cell biology, his research has provided some of the most detailed characterizations of NK cell responses against viruses, and his team was the first to identify memory and memory-like NK cells in humans and nonhuman primates. With over 100 publications in the field and over 60 as senior author, Dr. Reeves’ group continues to focus on cutting-edge approaches to harness NK cells in the context of vaccines and immunotherapeutics for HIV, CMV, HCV, influenza, SARS-CoV-2, congenital CMV, and cancer.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.